Search academic texts

Information × Registration Number 0223U000723, 0122U000554 , R & D reports Title To improve of antimycobacterial therapy with using new modified short-term treatment regimens in patients with chemoresistant pulmonary tuberculosis popup.stage_title Head Lytvynenko Nataliia A., Доктор медичних наук Registration Date 19-01-2023 Organization State organization "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky National academy of medical sciences of Ukraine" popup.description2  Object – 905 patients with MDR TB. Aim: to determine the optimal patient triage algorithms for the selection of optimal new modified short-term regimens of antimycobacterial therapy in patients with drug-resistant pulmonary tuberculosis, which will increase the effectiveness of treatment and save public funds. Methods: clinical, radiological, laboratory, microbiological. It is established that individualized treatment regimens should not last more than 12-14 months, taking into account the same number of repeated episodes of the disease. The expediency of prescribing modified short-term regimens of antimycobacterial therapy (AMBT) for patients with widespread processes in the lungs and previously treated with 2nd-line antimycobacterial drugs was studied based on the assessment of the periods of cessation of bacterial excretion in patients with ITR of different durations. It has been established that the period of individualized treatment regimens for 15 or more months should be planned in case of negative culture at a later date (5-6 or later months of treatment). The preliminary results of the use of AMBT modified short-term regimens with different composition and duration for patients with drug-resistant pulmonary tuberculosis have been studied. It was established that the effectiveness of treatment of various types of modified short-term regimens L of 9 months' duration, regardless of their composition, is high: successful treatment ranges from 88,1% to 95,3%. It was established that adverse events occur in patients with levofloxacin more often on 31,3%, including grade 3-4 adverse events. The technology for determining the optimal duration of individualized treatment regimens AMBT for patients with drug-resistant tuberculosis was developed, which made it possible to reduce the duration of individualized treatment regimens, which includes bedaquiline and repurposed drugs, to 12 months. Sphere of application – tuberculosis. Product Description popup.authors Barbova Anna I Veselovsʹkyy Leonid V Hritsova Nataliya A Davydenko Valentyna V Zhurylo Oleksandr A. Zaikov Sergey V Korotchenko Svitlana P Lafeta Anastasiya S Lytvynenko Nataliya A Lyubevich Rostislav L Pohrebna Maryna V Polinovska Lesia V Protsyk Lyubomyr M Siomak Olʹha V Senko Yuliia O Chobotar Oksana P Shcherbakova Lesya V Yalenko Victoria N popup.nrat_date 2023-01-19 Close